<DOC>
	<DOCNO>NCT01645748</DOCNO>
	<brief_summary>The purpose study evaluate tolerability efficacy combination weekly docetaxel , cisplatin , S-1 ( weekly TPS ) induction chemotherapy patient locally advanced head neck squamous cell carcinoma ( HNSCC ) .</brief_summary>
	<brief_title>Docetaxel , Cisplatin , S-1 ( TPS ) Induction Chemotherapy Locally Advanced Head Neck Cancer</brief_title>
	<detailed_description>Combination chemotherapy cisplatin fluorouracil ( CF ) standard treatment patient locally advance squamous cancer head neck . CF chemotherapy report increase survival disease free survival patient unresectable disease give definitive radiotherapy , show overall response rate 75-85 % include CR rate 25-35 % . To improvement treatment , docetaxel incorporate CF induction treatment show prolongation progression free survival overall survival large scale randomize phase III trial , therefore triple combination induction regimen would standard treatment advanced head neck cancer . Recently , introduction oral fluoropyrimidine show similar enhance response rate , also favorable safety convenience intravenous fluoropyrimidine advance gastric cancer . Of oral fluoropyrimidines , S-1 show promising preliminary result combination chemotherapy cisplatin head neck cancer . In patient advanced gastric cancer , phase I study S-1 , docetaxel cisplatin combination chemotherapy report recommended dos 40mg/m2 bid , 60mg/m2 ( D1 ) 60mg/m2 ( D1 ) , respectively . Therefore , aim study evaluate efficacy safety docetaxel , cisplatin S-1 combination chemotherapy accord dosage .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>locally advanced stage III IV squamous cell carcinoma larynx , oropharynx , hypopharynx ≥18 year old absolute neutrophil count ≥1,500/µL , platelets ≥100,000/µL serum bilirubin &lt; 2.0 mg/dL creatinine &lt; 1.5 mg/dL serum transaminase level less twice upper limit normal receive previous chemotherapy another malignancy current history distant metastasis history clinically significant cardiac disease within 6 month active serious infection nasopharyngeal carcinoma psychiatric illness would preclude obtain informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>head neck cancer</keyword>
	<keyword>docetaxel</keyword>
	<keyword>cisplatin</keyword>
	<keyword>S-1</keyword>
</DOC>